| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the London MS Clinic (Drs. Rice and Ebers, and J. Lesaux), London, Ontario; and the UBC MS Clinic (Drs. Oger and Paty, and B. Paszner), Vancouver, Canada.
Address correspondence and reprint requests to Dr. Rice, The London MS Clinic, LHSC-UC, 339 Windermere Road, London, Ontario, Canada N6A 5A5.
The fate of the neutralizing antibody (NAB) in MS patients treated with interferons remains unclear. We conducted a follow-up survey of NAB titers in 59 long-term treated patients from the London and Vancouver cohorts of the pivotal trial of interferon ß-1b. NAB were measured with the myxovirus protein A assay and an ELISA, at a mean follow-up that exceeded 8 years. NAB disappeared in the majority of patients.
This article has been cited by other articles:
|
|
 |
|
  A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study Neurology, November 3, 2009; 73(18): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
A. Noronha Neutralizing antibodies to interferon Neurology, June 12, 2007; 68(24_suppl_4): S16 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions Multiple Sclerosis, May 1, 2007; 13(1_suppl): 5 - 7. [PDF]
|
|
|
|
|
|
J. Oger and E. Gibbs Binding antibodies: Vancouver's perspective Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43. [Abstract] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 27, 2007; 68(13): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]
|
|
|
|
|
|
R. M Herndon, R. A Rudick, F. E Munschauer III, M. K Mass, A. M Salazar, M. E Coats, R. Labutta, J. R Richert, S. L Cohan, C. Genain, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex(R)treatment in patients with multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 409 - 419. [Abstract] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Gneiss, M Reindl, A Lutterotti, R Ehling, R Egg, M Khalil, T Berger, and F Deisenhammer Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity Multiple Sclerosis, October 1, 2004; 10(5): 507 - 510. [Abstract] [PDF]
|
|
|
|
|
|
A J. Petkau, R. A White, G. C Ebers, A. T Reder, W. A Sibley, F. D Lublin, D. W Paty, and IFNB Multiple Sclerosis Study Group Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2004; 10(2): 126 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner An improved ELISA for screening for neutralizing anti-IFN-{beta} antibodies in MS patients Neurology, November 25, 2003; 61(10): 1444 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner, J. Oger, and J. Palace The measurement of antibodies binding to IFN{beta} in MS patients treated with IFN{beta} Neurology, November 11, 2003; 61(90095): S18 - 20. [Full Text]
|
|
|
|
|
|
M. Kremenchutzky Long-term evolution of anti-INF{beta} antibodies in IFN{beta}-treated MS patients: The London, Canada, MS Clinic experience Neurology, November 11, 2003; 61(90095): S29 - 30. [Full Text]
|
|
|
|
 |
|
 N Lawrence, J Oger, T Aziz, J Palace, and A Vincent A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN {beta} J. Neurol. Neurosurg. Psychiatry, September 1, 2003; 74(9): 1236 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C H Polman, L Kappos, J Petkau, and A Thompson Neutralising antibodies to interferon {beta} during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1162 - 1162. [Full Text] [PDF]
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35. [Abstract] [PDF]
|
|
|
|
|
|
C. Polman, L. Kappos, R. White, F. Dahlke, K. Beckmann, C. Pozzilli, A. Thompson, J. Petkau, and D. Miller Neutralizing antibodies during treatment of secondary progressive MS with interferon {beta}-1b Neurology, January 14, 2003; 60(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
|
|
G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Rice The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta Arch Neurol, August 1, 2001; 58(8): 1297 - 1298. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis Arch Neurol, August 1, 2001; 58(8): 1299 - 1300. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Myhr, C. Ross, H. I. Nyland, K. Bendtzen, and C. A. Vedeler Neutralizing antibodies to interferon (IFN) {alpha}-2a and IFN {beta}-1a or IFN {beta}-1b in MS are not cross-reactive Neurology, November 28, 2000; 55(10): 1569 - 1572. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
